Sun Pharmaceutical Industries Limited
NSE: SUNPHARMA | Information Technology
Market Fundamentals
Stock Intelligence & News
Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal Manchanda
India's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and consumer healthcare. While US FDA approvals for complex generics remain a challenge, innovation and contract manufacturing offer significant future profit pools. Experts anticipate biosimilars could generate substantial revenue, and despite a slow start, GLP-1 drugs show long-term promise. Sun Pharma is highlighted as a preferred domestic investment.
Read Full Analysis →Zydus, Sun Pharma, Dr Reddy's In Focus: US Cancer Drug Shortage Puts India's Pharma Stocks In Focus
According to media reports, the regulator has communicated through the Indian Drug Manufacturers' Association (IDMA) to identify companies that can immediately supply ifosfamide injection, a generic chemotherapy drug used in the treatment of several cancers, including testicular, bladder and lung cancer.
Read Full Analysis →Sun Pharmaceutical Industries Limited
SUN PHARMACEUTICAL INDUSTRIES LIMITED has informed the Exchange regarding Acquisition (including agreement to acquire) |SUBJECT: Acquisition (including agreement to acquire)-XBRL
Read Full Analysis →AI-Powered Alerts for Your Portfolio
Alerfo's AI classifies every news event by type, severity, and market impact — then instantly notifies you via Email & WhatsApp only for the stocks you track.
Sun Pharma To Acquire 100% Share In Invocare Lifesciences For Rs 271 Crore
Sun Pharma described the acquisition as a strategic investment to strengthen its product portfolio.
Read Full Analysis →Sun Pharma, Alkem Labs, other pharma stocks gain despite stock market crash; Nifty Pharma rises for fourth day in a row
The Nifty Pharma index rose 1.4% on 8 June, defying the broader market selloff, supported by heavyweight stocks like JB Chemicals and Alkem Laboratories. Despite some losses in others, analysts suggest pharma stocks are resilient during market instability due to consistent healthcare demand.
Read Full Analysis →Indian Industry Celebrates $20.5 Billion Investment In US; Announce $1.1 Billion Projects
Indian pharmaceutical companies announced plans to invest more than $19.1 billion in the United States, anchored by Sun Pharmaceutical's planned $11.75 billion acquisition of New Jersey-based Organon & Co.
Read Full Analysis →Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited has informed the Exchange regarding a press release dated April 30, 2026, titled "SPARC Announces Sale of Priority Review Voucher for US $195 million". |SUBJECT: Press Release
Read Full Analysis →Sun Pharma shares rally 9% in two days after $12-bn Organon deal. Here's what Morgan Stanley, other brokerages say
Sun Pharmaceutical Industries' shares surged nearly 9% after announcing the $11.75 billion acquisition of Organon & Co., a global leader in women's health. The deal diversifies Sun Pharma's portfolio into women's health and biosimilars, with analysts from Morgan Stanley and Motilal Oswal expressing bullish sentiment, while JM Financial remains cautious about long-term value creation.
Read Full Analysis →Sun Pharma-Organon deal: How a $12-billion merger will reshape India's pharma landscape
Sun Pharma is set to nearly double its revenue to $12 billion with the acquisition of Organon, creating a global pharmaceutical giant. The deal leverages Organon's strengths in women's health, biosimilars, and established brands, aiming for significant growth despite geopolitical concerns. Integration plans and manageable debt are key to the strategic move.
Read Full Analysis →Bullish on power, energy, and BFSI; cautious on IT amid weak earnings: Devarsh Vakil
HDFC Securities sees opportunity in India's recovering equity markets. The firm favors power and energy sectors, citing infrastructure growth. Financials, including banks and NBFCs, are also preferred. However, the IT sector faces an underweight stance due to uncertain earnings. Sun Pharma's growth strategy and Varun Beverages' expansion are noted positively.
Read Full Analysis →Get instant alerts when SUNPHARMA breaks news
Join investors who track Sun Pharmaceutical Industries Limited on Alerfo — free plan available.
Set Free Alert →Frequently Asked Questions
What is the current trend for SUNPHARMA?
SUNPHARMA is currently showing a volatility profile consistent with its sector peers, with sentiment being actively monitored by Alerfo news scanners.
How can I set alerts for Sun Pharmaceutical Industries Limited?
You can set real-time price and news alerts by registering on the Alerfo platform and adding SUNPHARMA to your custom watchlist.